These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36640550)

  • 1. Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatment.
    Wang X; Wang Y; Xue Z; Wan W; Li Y; Qin H; Zhu Y; Tian F; Yang J
    J Colloid Interface Sci; 2023 Apr; 636():388-400. PubMed ID: 36640550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy.
    Chang X; Xing L; Wang Y; Zhou TJ; Shen LJ; Jiang HL
    Nanoscale; 2020 Apr; 12(16):8664-8678. PubMed ID: 32227023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.
    Pan T; Zhou Q; Miao K; Zhang L; Wu G; Yu J; Xu Y; Xiong W; Li Y; Wang Y
    Theranostics; 2021; 11(3):1192-1206. PubMed ID: 33391530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy.
    Yang MY; Lin YJ; Han MM; Bi YY; He XY; Xing L; Jeong JH; Zhou TJ; Jiang HL
    J Control Release; 2022 Nov; 351():623-637. PubMed ID: 36191673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment.
    Sang X; Wang Y; Xue Z; Qi D; Fan G; Tian F; Zhu Y; Yang J
    Front Immunol; 2021; 12():613907. PubMed ID: 33679754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization.
    Yan L; Hou C; Liu J; Wang Y; Zeng C; Yu J; Zhou T; Zhou Q; Duan S; Xiong W
    Sci China Life Sci; 2023 Nov; 66(11):2571-2586. PubMed ID: 37340175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
    Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
    J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial targeting of fibrosis-promoting macrophages with nanoscale metal-organic frameworks for idiopathic pulmonary fibrosis therapy.
    Hou J; Cong Y; Ji J; Liu Y; Hong H; Han X
    Acta Biomater; 2024 Jan; 174():372-385. PubMed ID: 38072226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling.
    Liu J; Wu Z; Liu Y; Zhan Z; Yang L; Wang C; Jiang Q; Ran H; Li P; Wang Z
    J Nanobiotechnology; 2022 May; 20(1):213. PubMed ID: 35524280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy.
    Wang B; Gao Y; Sun L; Xue M; Wang M; Zhang Z; Zhang L; Zhang H
    Biomaterials; 2023 Dec; 303():122404. PubMed ID: 37992600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling.
    Liu B; Jiang Q; Chen R; Gao S; Xia Q; Zhu J; Zhang F; Shao C; Liu X; Li X; Zhou H; Yang C; Huang H
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109424. PubMed ID: 36461589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schisandra Inhibit Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats via Suppressing M2 Macrophage Polarization.
    Guo Z; Li S; Zhang N; Kang Q; Zhai H
    Biomed Res Int; 2020; 2020():5137349. PubMed ID: 32884941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophages: friend or foe in idiopathic pulmonary fibrosis?
    Zhang L; Wang Y; Wu G; Xiong W; Gu W; Wang CY
    Respir Res; 2018 Sep; 19(1):170. PubMed ID: 30189872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of siPTPN13 and siNOX4
    Hou J; Ji Q; Ji J; Ju S; Xu C; Yong X; Xu X; Muddassir M; Chen X; Xie J; Han X
    Theranostics; 2021; 11(7):3244-3261. PubMed ID: 33537085
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.
    Kim TH; Lee YH; Kim KH; Lee SH; Cha JY; Shin EK; Jung S; Jang AS; Park SW; Uh ST; Kim YH; Park JS; Sin HG; Youm W; Koh ES; Cho SY; Paik YK; Rhim TY; Park CS
    Am J Respir Crit Care Med; 2010 Sep; 182(5):633-42. PubMed ID: 20463180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206
    Wang J; Xu L; Xiang Z; Ren Y; Zheng X; Zhao Q; Zhou Q; Zhou Y; Xu L; Wang Y
    Cell Death Dis; 2020 Feb; 11(2):136. PubMed ID: 32075954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress on the role and mechanism of 5-hydroxytryptamine and M2 macrophages in pulmonary interstitial fibrosis].
    Deng Y; Deng C; Zhu X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Sep; 35(9):1004-1008. PubMed ID: 37803964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-targeted delivery of siRNA to silence
    Mou Y; Wu GR; Wang Q; Pan T; Zhang L; Xu Y; Xiong W; Zhou Q; Wang Y
    Bioeng Transl Med; 2022 May; 7(2):e10280. PubMed ID: 35600643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histopathology of idiopathic pulmonary fibrosis in West Highland white terriers shares features of both non-specific interstitial pneumonia and usual interstitial pneumonia in man.
    Syrjä P; Heikkilä HP; Lilja-Maula L; Krafft E; Clercx C; Day MJ; Rönty M; Myllärniemi M; Rajamäki MM
    J Comp Pathol; 2013; 149(2-3):303-13. PubMed ID: 23664319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis.
    Chang X; Xing L; Wang Y; Yang CX; He YJ; Zhou TJ; Gao XD; Li L; Hao HP; Jiang HL
    Sci Adv; 2020 May; 6(22):eaba3167. PubMed ID: 32518825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.